With over 25 years of experience, Matt Becker specializes in trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.
Serving as lead trial counsel to multinational corporations across the life sciences, consumer products, technology, computer hardware and software, and industrial sectors, Matt has successfully handled more than 100 patent litigations, including numerous trials involving blockbuster drugs. He is often called upon to take over cases mid-stream, based on his proven track record of success.
Matt has particular experience litigating disputes involving intersecting intellectual property and antitrust issues, including matters involving standard-essential patents.
In addition to his patent litigation practice, Matt holds various leadership positions within the firm. He is a member of the firm’s Executive Committee and served as the firm’s managing partner from 2017-2023. Under his guidance, the firm experienced record growth and expansion, acquiring talented lateral partners and expanding its geographic footprint by opening an office in San Francisco to better serve the firm’s West Coast client base.
Matt's accomplishments have earned him recognition as a leading intellectual property litigator by Benchmark Litigation, The National Law Journal, and Chambers.
Professional Activities
- American Bar Association, Section of Intellectual Property Law, Federal Practice Committee
- Intellectual Property Owners Association
- Connecticut Intellectual Property Law Association
- Connecticut Bar Association, Section of Intellectual Property Law
Experience
- Representation of a major generic pharmaceutical company in Hatch-Waxman patent infringement action pending in the District of New Jersey involving methylphenidate hydrochloride extended-release capsules.
- Defense of pharmaceutical company in Hatch-Waxman litigation pending in the Southern District of Indiana relating to duloxetine hydrochloride capsules.
- Representation of major generic pharmaceutical company in parallel actions in the District of New Jersey and the District of Delaware involving dexmethylphenidate hydrochloride extended release capsules.
- Defense of generic pharmaceutical company in Hatch-Waxman patent litigation relating to atomoxetine hydrochloride capsules.
- Various counseling projects for pharmaceutical companies involving patent analysis relating to Abbreviated New Drug Applications.
- Successful defense to verdict of an international manufacturer of electronic fans and hard drive motors against claims of infringement of multiple patents covering brushless direct current motors used in computer equipment.
- Defense of a major manufacturer of nuclear detection equipment in a patent infringement action involving a nine-figure damage claim in the U.S. District Court in Knoxville, Tennessee, in which a favorable settlement was obtained at the outset of trial.
- Representation in multiple patent and commercial actions of a leading manufacturer of electronic environmental monitors which were favorably resolved through settlement and summary judgment.
- Successful procurement of injunctive relief on behalf of a prominent pharmaceutical manufacturer in a trade secret action against a competitor.
- Representation of aerospace corporation in breach of license agreement claim in which a seven figure settlement was obtained.
- Representation of manufacturer of specialty optical fibers in action alleging infringement of ten patents. Obtained dismissal of claims relating to seven patents, and favorable settlement of remaining claims.
- Representation of a major software manufacturer in a highly publicized business method patent case involving online travel services.
- Defense of a leading manufacturer of hand tools in patent infringement action in which multiple patents were asserted, and in which all claims were dismissed with prejudice following a successful Markman hearing.
- Representation of a Fortune 500 forest products corporation in multiple patent infringement and trade secret litigation matters and in intellectual property strategic counseling.
- Representation of a Fortune 100 corporation in obtaining a multimillion-dollar judgment and permanent injunction after a three-year litigation against a competitor based on the misappropriation and misuse of proprietary drawings and technology.
- Prosecution and defense of various patent infringement lawsuits in the U.S. District Court for the District of Connecticut on behalf of a manufacturer of compact disc labeling equipment and software.
- Defense of a leader in the electronic billing field against patent infringement claims, and negotiation of acquisition of the patent-in-suit.
- Defense of U.S. and German manufacturers of multi-gas analyzers against claims of patent infringement and trade secret misappropriation.
- Successful defense of Fortune 500 corporation in patent infringement action involving pneumatic shears.
Honors
- LMG Life Sciences – Life Sciences Star (2020 – 2024)
- Named to The National Law Journal’s list of Intellectual Property Trailblazers (2020)
- World's Leading Patent Professionals (2020 – 2023), IAM Patent 1000
- Benchmark Litigation – CT Litigation Star: Intellectual Property (2020 – 2024)
- Best Lawyers in America (2015 – 2024)
- Chambers USA – Connecticut: Litigation (2016 – 2020)
- Super Lawyers (2012 – 2021, 2023)
News
- Axinn Partners Named Life Sciences Stars by LMG Life Sciences
- Nine Axinn Partners Ranked in the 2024 Edition of Benchmark Litigation
- Axinn Attorneys Named to Best Lawyers 2024
- Axinn Shortlisted for Three 2023 LMG Life Sciences Americas Awards
- Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
- View More ›
Thought Leadership
- "He'll Hit the Ground Running:" IP Attorneys Point to Stark's Experience Juggling Busy Patent Docket as Asset on Federal Circuit, Delaware Law Weekly, November 5, 2021
- Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases, Axinn Update, January 2020
- Joint Infringement Post-Akamai Part Two: Decisions Since Akamai and Practice Insights, The Intellectual Property Strategist, February 2017
- Joint Infringement Post-Akamai Part One: Exploring the New Joint Infringement Standard, The Intellectual Property Strategist, January 2017
- Federal Circuit Flips On Willfulness Questions in Stryker v. Zimmer, Medical Device Daily, September 14, 2016
- 4 Lessons From A Year Of Claim Construction Under Teva, Law360, January 25, 2016
- Law360's Q&A With Axinn's Matthew Becker, Law360, July 15, 2013
- Raising the Bar of Patentability, Connecticut Law Tribune, April 21, 2008
- What is Patentable?, IP Law and Business, October 2007
- Interpreting the Entire Market Value Rule, Connecticut Law Tribune Intellectual Property Supplement, July 16, 1999
- Expert Testimony After Daubert: What is Admissible?, Environmental Compliance and Litigation Strategy, December 1995
Events
- ACI 20th Paragraph IV Conference
- ACI 15th Annual Paragraph IV Disputes Conference
- ACI 8th Annual Advanced Summit on Medical Device and MedTech Patents
- ACI 7th Annual Advanced Summit on Medical Device and MedTech Patents
- Centerforce 4th Annual IP Strategy Summit - Silicon Valley
- SCOTUS Update: Impact of Halo and Stryker on Enhanced Patent Damages Assessments
- Assessing the Patent and FDA Strategies for Follow-On Biologics to Maximize Success
Education
- JD, summa cum laude – Indiana University School of Law (1991)
- BS, Chemistry – Indiana University (1988)
Admissions
- Connecticut
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the District of Connecticut
- U.S. Patent & Trademark Office
- Judicial Panel Multi-District Litigation
Spotlight
"He knows patent law inside out" and "…is extremely smart and comes up with excellent strategies."
– Chambers USA
"… Matthew Becker is a seasoned litigator who has an excellent track record of advising large multinational clients in vitally important patent matters." – IAM Patent 1000 2023